Treatment of Coccidioides immitis pneumonia in two horses with fluconazole.

Summary

# Editorial Summary: Fluconazole Treatment for Equine Coccidioidomycosis Coccidioides immitis pneumonia represents a significant clinical challenge in horses, with pulmonary infection frequently progressing to severe systemic disease and historically carrying a poor prognosis due to limited therapeutic options and substantial treatment costs. Higgins and colleagues documented two clinical cases treated with fluconazole, a triazole antifungal agent sourced through a compounding pharmacy, demonstrating the feasibility of this approach in equine practice. Both horses responded successfully to fluconazole therapy, indicating that this orally bioavailable azole may offer a more economical and accessible alternative to previously established but prohibitively expensive treatment protocols. For practitioners managing horses in endemic regions (particularly the southwestern United States), this work suggests fluconazole warrants consideration as a cost-effective option for pulmonary coccidioidomycosis, though individual pharmacokinetic data and longer-term outcome monitoring would strengthen clinical confidence in the protocol. Further investigation into optimal dosing regimens, treatment duration, and outcomes across larger case populations remains valuable for standardising this therapeutic approach.

Read the full abstract on PubMed

Key Findings

• •Two horses with pulmonary coccidioidomycosis were successfully treated with fluconazole from a compounding pharmacy
• •Fluconazole treatment represents a potentially less expensive alternative to previous therapeutic approaches for equine coccidioidomycosis
• •Pulmonary coccidioidomycosis in horses can progress to severe systemic disease if untreated

Conditions Studied